CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor!
<< View More Conferences
2018 New York Lung Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Hanna on Consolidation Immunotherapy in Stage III NSCLC
Dr. Herbst on Immune Resistance in Lung Cancer
Dr. Perez-Soler on Efficiency of NGS in Lung Cancer
Oncology Conference Articles
More Data Needed on Changing Systemic Therapy in NSCLC
There is limited data on when and whether oncologists should change systemic therapy for patients with non–small cell lung cancer, but some studies provide useful guidance.
Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC Options
In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.
Herbst Highlights Next Steps With Immunotherapy in Lung Cancer
Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.
Broad Panel NGS Testing Grows in Value for NSCLC
Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.
Camidge Breaks Down Oncogene-Driven NSCLC
D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non–small cell lung cancer.
Acquired Resistance Remains Key Challenge in Oncogene-Driven NSCLC
Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.
Uncertainty Surrounds Nondriver NSCLC Treatment After Progression
Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.
Drilon Sheds Light on Lesser-Known Markers in NSCLC
Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.
Future Research and the Clinical Management of mCRC
Dabrafenib Plus Trametinib Demonstrates Activity in GI Cancers
FDA Approves Frontline Eltrombopag for Severe Aplastic Anemia
Novel Drug Combination Shows Early Activity in Microsatellite Stable CRC
Durvalumab Combo Misses OS Endpoint in Frontline Metastatic NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.